UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/597,747	08/06/2006	Pinhas Gilboa	231660-120	3893
37374 7590 09/11/2008 INSKEEP INTELLECTUAL PROPERTY GROUP, INC 2281 W. 190TH STREET SUITE 200			EXAMINER	
			WITCZAK, CATHERINE	
TORRANCE, CA 90504			ART UNIT	PAPER NUMBER
			3767	
			NOTIFICATION DATE	DELIVERY MODE
			09/11/2008	ELECTRONIC

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

inskeepstaff@inskeeplaw.com

	Application No.	Applicant(s)			
	10/597,747	GILBOA, PINHAS			
Office Action Summary	Examiner	Art Unit			
	CATHERINE N. WITCZAK	3767			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
<ul> <li>1) Responsive to communication(s) filed on 27 Au</li> <li>2a) This action is FINAL. 2b) This</li> <li>3) Since this application is in condition for allowant closed in accordance with the practice under E</li> </ul>	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1-30 is/are pending in the application. 4a) Of the above claim(s) 16-30 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-15 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examiner	r election requirement.				
10) ☐ The drawing(s) filed on is/are: a) ☐ acce Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correcti 11) ☐ The oath or declaration is objected to by the Ex-	drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 8/27/2008.	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6)  Other:	nte			

### **DETAILED ACTION**

#### **Priority**

It is noted that this application appears to claim subject matter disclosed in prior Applications No. PCT/IL05/00159, filed 2/9/2005 and US 60/542280, filed 2/9/2004. A reference to the prior application must be inserted as the first sentence(s) of the specification of this application or in an application data sheet (37 CFR 1.76), if applicant intends to rely on the filing date of the prior application under 35 U.S.C. 119(e), 120, 121, or 365(c). See 37 CFR 1.78(a). For benefit claims under 35 U.S.C. 120, 121, or 365(c), the reference must include the relationship (i.e., continuation, divisional, or continuation-in-part) of all nonprovisional applications. If the application is a utility or plant application filed under 35 U.S.C. 111(a) on or after November 29, 2000, the specific reference to the prior application must be submitted during the pendency of the application and within the later of four months from the actual filing date of the application or sixteen months from the filing date of the prior application. If the application is a utility or plant application which entered the national stage from an international application filed on or after November 29, 2000, after compliance with 35 U.S.C. 371, the specific reference must be submitted during the pendency of the application and within the later of four months from the date on which the national stage commenced under 35 U.S.C. 371(b) or (f) or sixteen months from the filing date of the prior application. See 37 CFR 1.78(a)(2)(ii) and (a)(5)(ii). This time period is not extendable and a failure to submit the reference required by 35 U.S.C. 119(e) and/or 120, where applicable, within this time period is considered a waiver of any benefit of such prior application(s) under 35 U.S.C. 119(e), 120, 121 and 365(c). A benefit claim filed after the required time period may be accepted if it is accompanied by a grantable petition to accept an unintentionally delayed benefit claim under 35 U.S.C. 119(e), 120, 121 and 365(c). The petition must be accompanied by (1) the reference required by 35 U.S.C. 120 or 119(e) and 37 CFR 1.78(a)(2) or (a)(5) to the prior application (unless previously submitted), (2) a

surcharge under 37 CFR 1.17(t), and (3) a statement that the entire delay between the date the claim was due under 37 CFR 1.78(a)(2) or (a)(5) and the date the claim was filed was unintentional. The Director may require additional information where there is a question whether the delay was unintentional. The petition should be addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

If the reference to the prior application was previously submitted within the time period set forth in 37 CFR 1.78(a), but not in the first sentence(s) of the specification or an application data sheet (ADS) as required by 37 CFR 1.78(a) (e.g., if the reference was submitted in an oath or declaration or the application transmittal letter), and the information concerning the benefit claim was recognized by the Office as shown by its inclusion on the first filing receipt, the petition under 37 CFR 1.78(a) and the surcharge under 37 CFR 1.17(t) are not required. Applicant is still required to submit the reference in compliance with 37 CFR 1.78(a) by filing an amendment to the first sentence(s) of the specification or an ADS. See MPEP § 201.11.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 1. Claims 1-9, 11-13, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Clark et al (US 5,713,853) in view of Sher (US 2006/0015126).

Clark et al disclose in Figure 25 and 26 an anchorable device for deployment within a biological conduit comprising a catheter arrangement (704) and a steering mechanism (712) comprising a guidewire, an anchoring mechanism (706) including one expandable element initially assuming a collapsed state and

having a lumen (710) for introduction of a filler material, a compartment (one of the tubular members of the expansible portion) for receiving a fluid therapeutic substance from a dispensing arrangement (126), and a second compartment (another expansible tubular member) for receiving a second solution.

Clark et al disclose the claimed invention except for the central axis of the catheter lying at substantially non-zero axis relative to the central axis of the biological conduit. Sher teaches in Figure 9 it is known position a catheter such that the central axis of the catheter lies at substantially a non-zero axis relative to the central axis of the biological conduit. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of Clark et al by positioning the central axis of the catheter so as to lie at substantially anon-zero axis relative to the central axis of the biological conduit as taught by Sher, since such a modification would allow for accurate placement of the device.

2. Claim 10 is rejected under 35 U.S.C. 103(a) as being unpatentable over Clark et al in view of Sher, in further view of Durgin, Jr. et al (US 5,522,815).

Clark et al as modified by Sher disclose the claimed invention except for disclosing the device including a cannula deployable to project beyond the distal portion of the catheter. Durgin et al teach in Figure 3 it is known to use a cannula deployable to project beyond the distal portion of the catheter. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the device of Clark et al as modified by Sher with a cannula deployable to project beyond the distal portion of the catheter as taught by Durgin et al, since such a modification would allow for injections to be made using therapeutic access to tissue within the body.

3. Claim 14 is rejected under 35 U.S.C. 103(a) as being unpatentable over Clark et al in view of Sher, in further view of Kaplan (US 2002/0173689).

Clark et al as modified by Sher disclose the claimed invention except for disclosing the device

Art Unit: 3767

carrying a brachytherapy seed. Kaplan teaches in paragraph [0053] it is known to incorporate brachytherapy seeds into therapy devices. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the device of Clark et al as modified by Sher with a brachytherapy seeds as taught by Kaplan, since such a modification would allow for specific treatment of a particular disease.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERINE N. WITCZAK whose telephone number is (571)272-7179. The examiner can normally be reached on Monday through Friday, 8-5 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/597,747

Page 6

Art Unit: 3767

/Catherine N Witczak/ Examiner, Art Unit 3767 /Kevin C. Sirmons/ Supervisory Patent Examiner, Art Unit 3767